Annovis Bio, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.02 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 43.46M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Details
| Name | Annovis Bio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 7 |
| Founded | 2008 |
| Ipo Date | 2020-01-29 |
| Ceo | Maria Maccecchini |
| Country | United States |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 6.00 |
| Isin | US03615A1088 |
| Cusip | 03615A108 |
| Cik | 1477845 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Maria L. Maccecchini Ph.D. | Founder, Acting Chief Financial Officer, Chief Executive Officer, President and Executive Director |
| Dr. Cheng Fang Ph.D. | Chief Scientific Officer |
| Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations |
| Blake Jensen M.B.A. | Head of Quality |
| Hilda Maibach | Senior Vice President of Statistics |
Contact
| Address | 101 Lindenwood Drive, Suite 225, Malvern, Pennsylvania 19355, United States |
| Phone | 484 875 3192 |
| Website | https://www.annovisbio.com |